BCL2 and acute myeloid leukemia: Significantly, our study clearly demonstrated that a strong synergistic effect was observed in two ABT-199-resistant cell lines when ABT-199 was combined with P1D-34, highlighting the potential therapeutic value of targeted Pin1 degradation for the treatment of Bcl-2 inhibitor-resistant AML.